O-008 Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
Titel:
O-008 Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
Auteur:
Rimassa, L. Bozzarelli, S. Cordio, S. Toppo, L. Lonardi, S. Zaniboni, A. Bordonaro, R. Liguigli, W. Zagonel, V. Tronconi, M.C. Di Tommaso, L. Giordano, L. Santoro, A.